Short Interest Alert: What’s in BIONIK LABORATORIES CORPORATION (OTCMKTS:BNKL) After Decline in Shorted Shares?

November 28, 2016 - By Marguerite Chambers   ·   0 Comments

Short Interest Alert: What’s in BIONIK LABORATORIES CORPORATION (OTCMKTS:BNKL) After Decline in Shorted Shares?

The stock of BIONIK LABORATORIES CORPORATION (OTCMKTS:BNKL) registered a decrease of 27.91% in short interest. BNKL’s total short interest was 3,100 shares in November as published by FINRA. Its down 27.91% from 4,300 shares, reported previously. With 6,400 shares average volume, it will take short sellers 1 days to cover their BNKL’s short positions. The stock closed at $0.75 during the last session. It is down 29.91% since April 25, 2016 and is downtrending. It has underperformed by 35.92% the S&P500.

Bionik Laboratories Corp. , formerly Drywave Technologies, Inc., is a medical device and robotics company. The company has a market cap of $34.77 million. The Firm is focused on providing rehabilitation solutions and developing transformational technologies and solutions to individuals with neurological disorders, specializing in the designing, developing and commercializing of physical rehabilitation technologies, prosthetics and assisted robotic products. It has a 91.13 P/E ratio. It has over three products on the market and approximately three products in various stages of development.

BNKL Company Profile

Bionik Laboratories Corp. (Bionik), formerly Drywave Technologies, Inc., incorporated on June 25, 2013, is a medical device and robotics company. The Firm is focused on providing rehabilitation solutions and developing transformational technologies and solutions to individuals with neurological disorders, specializing in the designing, developing and commercializing of physical rehabilitation technologies, prosthetics and assisted robotic products. It has over three products on the market and approximately three products in various stages of development. The InMotion Systems include the InMotion ARM, InMotion HAND, InMotion Wrist and InMotion ANKLE are designed to provide patent-adaptive therapy in a manner that has been clinically verified to manage neuro-recovery. The Firm is also engaged in developing a lower-body exoskeleton, ARKE, which creates to allow paraplegics, as well as other wheelchair users the ability to rehabilitate through walking. It also has over two earlier stage development technologies: APOLLO, a prosthetic knee, and Chronos, a cloud patient queuing system.

More notable recent Bionik Laboratories Corp (OTCMKTS:BNKL) news were published by: Prnewswire.com which released: “Bionik Laboratories Raises $6.2 Million” on February 27, 2015, also Prnewswire.com with their article: “Bionik Laboratories Enters into Merger Agreement to Acquire Interactive Motion …” published on March 07, 2016, Prnewswire.com published: “Bionik Laboratories Announces Closing of Acquisition of Interactive Motion …” on April 21, 2016. More interesting news about Bionik Laboratories Corp (OTCMKTS:BNKL) were released by: Globenewswire.com and their article: “Bionik Laboratories Provides Corporate Update and Business Outlook” published on October 27, 2016 as well as Prnewswire.com‘s news article titled: “Bionik Laboratories Reports Second Quarter Fiscal Year 2017 Financial Results” with publication date: November 15, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marguerite Chambers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>